Krystal Biotech announces FDA approval of update VYJUVEK label

Krystal Biotech (KRYS) announced that the United States Food and Drug Administration, FDA, approved a label update for VYJUVEK that expands the VYJUVEK eligible patient population to include dystrophic epidermolysis bullosa, DEB, patients from birth and provides patients full flexibility with respect to VYJUVEK application and managing wound dressings. “We believe these changes further reinforce VYJUVEK’s leadership position as the most flexible, convenient, and disease modifying medicine to treat DEB patients in the United States,” said Krish Krishnan, Chairman and CEO of Krystal Biotech. “Moreover, by providing patients and their caregivers the ability to apply VYJUVEK themselves, we have made it easier for patients to integrate VYJUVEK into their daily routines and lifestyle. Overall, we believe that these advancements solidify VYJUVEK as the standard of care for all DEB wounds, regardless of wound size and severity, and will further improve compliance.”